← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Synergene Therapeutics, Inc.
Washington, DC
$4,391,942
Total funding
9
Grants
Funding over time
peak $588.3K · FY2005–14$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$4,391,942 · 9
By mechanism
R42$1,794,326 · 2
N43$1,619,275 · 3
R41$978,341 · 4
Investigators at Synergene Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
A Dual Molecular/Tumor Targeting Therapy for PanCa$588,264
R42 · FY2005 · CA
A Dual Molecular/Tumor Targeting Therapy for PanCa$571,402
R42 · FY2004 · CA
SBIR PROPOSAL FOR PHS 2009-1 TOPIC 266 FOR A TARGETED NANOCOMPLIX FOR EARLY DETE$498,331
N43 · FY2010 · CA
SBIR PROPOSAL FOR PHS 2009-1 TOPIC 266 FOR A TARGETED NANOCOMPLIX FOR EARLY DETE$498,331
N43 · FY2011 · CA
A Tumor-Specific Nanoimmunocomplex Markedly Improves MR Imaging$478,857
R41 · FY2006 · CA
Immunoliposome-Mediated Gene Therapy for Prostate Cancer$317,330
R42 · FY2003 · CA
Immunoliposome-Mediated Gene Therapy for Prostate Cancer$317,330
R42 · FY2002 · CA
HHSN261201400038C;SBIR TOPIC 326 DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS;PROJECT TITLE: CROSSING THE BBB AND TARGETING CSCS FOR GBM THERAPY;CONTRACT PERFORMANCE PERIOD 09$222,900
N43 · FY2014 · CA
Enhancement of Tumor-Targeted Transgene Expression$201,742
R41 · FY2004 · CA
SBIR PROPOSAL FOR PHS 2009-1 TOPIC 266 FOR A TARGETED NANOCOMPLIX FOR EARLY DETE$199,978
N43 · FY2009 · CA
TARGETED NANOCOMPLEXED IRON OXIDE FOR EARLY DETECTION WITH HYPERTHERMIA TREATMEN$199,735
N43 · FY2009 · CA
A Dual Molecular/Targeting Therapy for PanCa$158,980
R41 · FY2003 · CA
Targeting Stealth Liposome for Cancer Gene Therapy$138,762
R41 · FY2002 · CA